Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
Epcoritamab en tislelizumab in de sluis geplaatst
nov 2023 | Lymfoom, Maag-darm-leveroncologie